Fate Therapeutics, Inc.
FATE
$1.12
$0.010.90%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 17.07% | -12.42% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 17.07% | -12.42% | |||
| Cost of Revenue | -86.89% | 70.00% | |||
| Gross Profit | 93.04% | -80.03% | |||
| SG&A Expenses | -16.90% | -56.60% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.40% | -12.20% | |||
| Operating Income | 10.45% | 12.19% | |||
| Income Before Tax | 9.44% | 27.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 9.44% | 27.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.44% | 27.86% | |||
| EBIT | 10.45% | 12.19% | |||
| EBITDA | 11.22% | 10.07% | |||
| EPS Basic | 9.57% | 28.21% | |||
| Normalized Basic EPS | 9.52% | -0.05% | |||
| EPS Diluted | 9.57% | 28.21% | |||
| Normalized Diluted EPS | 9.52% | -0.05% | |||
| Average Basic Shares Outstanding | 0.13% | 0.49% | |||
| Average Diluted Shares Outstanding | 0.13% | 0.49% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||